A
15.60
-0.71 (-4.32%)
| 前收盘价格 | 16.31 |
| 收盘价格 | 16.18 |
| 成交量 | 1,201,046 |
| 平均成交量 (3个月) | 1,033,304 |
| 市值 | 1,732,939,392 |
| 价格/销量 (P/S) | 0.660 |
| 股市价格/股市净资产 (P/B) | 6.30 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业利益率 (TTM) | 16,317.06% |
| 稀释每股收益 (EPS TTM) | -3.10 |
| 季度收入增长率 (YOY) | -99.60% |
| 总债务/股东权益 (D/E MRQ) | 0.69% |
| 流动比率 (MRQ) | 12.05 |
| 营业现金流 (OCF TTM) | -206.98 M |
| 杠杆自由现金流 (LFCF TTM) | -182.62 M |
| 资产报酬率 (ROA TTM) | -40.72% |
| 股东权益报酬率 (ROE TTM) | -83.24% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Amylyx Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.6
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.63 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 9.54% |
| 机构持股比例 | 85.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Commodore Capital Lp | 31 Dec 2025 | 5,650,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 34.00 (HC Wainwright & Co., 117.95%) | 购买 |
| 中 | 21.00 (34.62%) | |
| 低 | 19.00 (B of A Securities, 21.80%) | 购买 |
| 平均值 | 24.67 (58.14%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 14.39 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (117.95%) | 购买 | 15.05 |
| 10 Feb 2026 | 28.00 (79.49%) | 购买 | 14.89 | |
| Stifel | 03 Mar 2026 | 21.00 (34.62%) | 购买 | 14.11 |
| B of A Securities | 20 Feb 2026 | 19.00 (21.79%) | 购买 | 14.01 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合